Advanced Blockchain AG

  • WKN: A0M93V
  • ISIN: DE000A0M93V6
  • Land: Deutschland

Nachricht vom 23.11.2021 | 08:55

Advanced Blockchain AG: Expects Higher Income Due to Shifts in Digital Assets

DGAP-News: Advanced Blockchain AG / Key word(s): Forecast/Cryptocurrency / Blockchain
23.11.2021 / 08:55
The issuer is solely responsible for the content of this announcement.

Advanced Blockchain AG (Frankfurt, primary market Düsseldorf, XETRA: ISIN DE000A0M93V6) expects an increased profit for the year compared to the communicated half-year result due to rebalancing of its digital asset portfolio. The balance sheet income will amount to at least a mid-single-digit million EUR amount before taxes within the Advanced Blockchain Group.

This rebalancing of crypto assets acquired by the organization in the years 2017 to 2020, will result in the ability to make new investments in more currently promising digital assets in a timely manner. A reduction of investments in digital assets overall is not planned, as Advanced Blockchain AG continues to assume a dynamic development of the market.

Reallocations will be made over an extended period of time, potentially extending into the next fiscal year, depending on market conditions across centralized and decentralized exchanges for crypto assets.

For more information on Advanced Blockchain AG and its projects and investments, please visit

23.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021